Switch from metformin monotherapy to bitherapy with metformin and repaglinide to achieve glycated haemoglobin target in type 2 diabetes (REPAMET Study)

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 3, Issue 4, 2009, Pages 224-227

  Hermans, M P ^a   D'Hooge, D ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Diabetes; HbA1c; Metformin; Observational; Repaglinide; SMBG

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; REPAGLINIDE;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OPEN STUDY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 70849123746     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2009.07.003     Document Type: Article

References (12)

1. American Diabetes Association. Standards of medical care in diabetes-2008 (Position Statement). Diabetes Care 31 Suppl. 1 (2008) S12-S54
2. European Diabetes Policy Group, International Diabetes Federation. A desktop guide to Type 2 diabetes mellitus. Diabetes Med 16 (1999) 716-730
3. I.N.A.M.I. Réunion de consensus 13 Nov 2003. L'usage adéquat des antidiabétiques oraux. R.I.Z.I.V. Consensusvergadering 13 November 2003. Het doelmatig gebruik van de orale antidiabetica.
4. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
6. Stratton I., Adler A., Neil H., Matthews D., Manley S., Cull C., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
7. Raskin P. Oral combination therapy: repaglimide plus metformin for treatment of type 2 diabetes. Diabetes Obes Metab (2008)
8. Moses R., Slobodniuk R., Boyages S., Colagiuri S., Kidson W., Carter J., et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 22 (1999) 119-124
9. Johansen O.E., and Birkeland A.I. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs 7 5 (2007) 319-335
10. Mehuys E., De Bolle L., Van Bortel L., Annemans L., Van Tongelen I., Remon J.P., et al. Medication use and disease management of type-2 diabetes in Belgium. Pharm World Sci 30 (2008) 51-56
11. Selvais P.L., Amoussou-Guenou K.D., and Hermans M.P. Adhesion to a diabetes patient's association predictive of better metabolic control. Diabetes Metab 34 (2008) 279-282
12. Ligthelm R.J., Borzì V., Gumprecht J., Kawamori R., Wenying Y., and Valensi P. Importance of observational studies in clinical practice. Clin Ther 29 (2007) 1284-1292